August 29, 2026
RESEARCH USE ONLY. Retatrutide is an investigational compound and is not approved by the FDA for human or veterinary use. Products discussed on this site are supplied strictly for laboratory and research purposes. Nothing on this page is medical advice or a dosing recommendation for any person or animal.
Comparison pages on these two compounds almost always present a table of weight-loss percentages side by side. That table is misleading, and it is worth explaining exactly why before showing you any numbers at all.
Sourced fact: As of 19 August 2026, no head-to-head trial of retatrutide versus tirzepatide has been published. One is running — TRIUMPH-5, NCT06662383 — with an estimated primary completion of 1 November 2026 and study completion of 1 December 2026. It is listed as active, not recruiting, with approximately 800 participants and an active comparator arm of tirzepatide. Its primary outcome is percent change from baseline in body weight at week 80. [1]
Inference: Every comparison of these two molecules currently in circulation — including this one — is a cross-trial indirect comparison. Cross-trial comparisons are not evidence of superiority. The trials differ in population, baseline weight, duration, dose ladder, and blinding. Until TRIUMPH-5 reads out, the honest position is that the direct question has not been answered.
| Retatrutide | Tirzepatide | |
|---|---|---|
| Receptors | GIPR, GLP-1R, GCGR | GIPR, GLP-1R |
| Relative potency | ~8.9× native GIP at GIPR; ~0.4× native GLP-1 at GLP-1R; ~0.3× native glucagon at GCGR [2] | Equal affinity to native GIP at GIPR; ~5× weaker than native GLP-1 at GLP-1R [3] |
| FDA status | Not approved for any indication [4] | Approved — Mounjaro (T2D), Zepbound (obesity, OSA) [5] |
Sourced fact: Tirzepatide’s characterisation is precise and worth quoting in full: it “is an imbalanced dual agonist in favor of GIPR over GLP-1R activity as the molecule shows equal affinity for the GIPR compared with native GIP but binds the GLP-1R with approximately 5-fold weaker affinity than native GLP-1.” The same paper reports it “is a potent, partial agonist (51% efficacious) at the GLP-1R, while retaining full agonism at the GIPR.” [3]
Note on attribution: this paper is frequently cited as “Coskun et al., JCI Insight 2020.” The correct first author is Willard FS. Coskun is not an author on it.
Inference: Both molecules lean toward GIPR. The structural difference between them is the glucagon receptor arm, which retatrutide has and tirzepatide does not. Whatever separates them clinically, if anything does, most plausibly traces to that.
Sourced fact: Tirzepatide holds FDA approval under two brand names. Zepbound is “indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition” and “to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.” [5] Mounjaro is indicated for glycemic control in type 2 diabetes in adults and pediatric patients aged 10 and older. [6]
Sourced fact: Both tirzepatide labels carry a boxed warning: “In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.” [6]
Sourced fact: Retatrutide has no FDA approval and no approved label. A query to Drugs@FDA returns zero records for it. Lilly states it plans to submit a Biologics License Application “in Q1 2027.” [7]
Inference: One of these molecules has been through FDA review, has a label, has a boxed warning, and has published safety data across a large approved population. The other has not. That asymmetry is not captured anywhere in a weight-loss percentage table, and for most purposes it is the more consequential difference.
These are the primary endpoints as each trial’s own publication reports them. They are not comparable to each other. Different populations, durations, and designs.
Sourced fact: Phase 2, 338 adults with obesity, 48 weeks. “At 48 weeks, the least-squares mean percentage change in the retatrutide groups was −8.7% in the 1-mg group, −17.1% in the combined 4-mg group, −22.8% in the combined 8-mg group, and −24.2% in the 12-mg group, as compared with −2.1% in the placebo group.” [8] The abstract reports no confidence intervals.
Sourced fact: Only one Phase 3 retatrutide trial has been published in a peer-reviewed journal — TRANSCEND-T2D-1, Lancet, June 2026. [9] Phase 3 obesity results (the TRIUMPH program) exist as sponsor press releases and conference presentations only.
Sourced fact: SURMOUNT-1, Phase 3, 2,539 adults with obesity without diabetes, 72 weeks. “The mean percentage change in weight at week 72 was −15.0% (95% CI, −15.9 to −14.2) with 5-mg, −19.5% (95% CI, −20.4 to −18.5) with 10-mg, and −20.9% (95% CI, −21.8 to −19.9) with 15-mg and −3.1% (95% CI, −4.3 to −1.9) with placebo.” [10]
Sourced fact: The same trial reports: “Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively.” [10]
Inference on the evidence gap: tirzepatide’s obesity data come from a completed, peer-reviewed, 2,539-participant Phase 3 with confidence intervals. Retatrutide’s peer-reviewed obesity data come from a 338-participant Phase 2 without confidence intervals in the abstract. Those are not the same tier of evidence, independent of what the point estimates say.
Sourced fact: The retatrutide Phase 2 abstract records: “Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter.” [8]
Sourced fact: Glucagon receptor agonism is hypothesised to raise energy expenditure — “Gcg enhances energy expenditure, mediated in part by the activation of brown adipose tissue and thermogenesis” — but a 2025 review states that “long-term safety data are currently lacking, representing a critical gap in the clinical translation of these agents.” [11]
Inference: The glucagon arm is what makes retatrutide structurally distinct from tirzepatide, and it is simultaneously the part with the least mature long-term human safety record. Anyone comparing the two on efficacy alone is comparing on the dimension where the difference is least established and ignoring the dimension where it is most.
This is not medical advice, not a treatment comparison, and not a recommendation of either compound for any person. It reports what published trials measured and what FDA labels say. It deliberately declines to declare a winner, because the trial that would answer that question has not reported.
When TRIUMPH-5 publishes, we will update this page with its actual results rather than leaving an indirect comparison standing.
PureLab Performance supplies retatrutide and tirzepatide for laboratory research use. Every compound page publishes its own specification block — lot, chromatographic purity, label claim, identity method and testing laboratory — or states plainly that the certificate is pending. Related: how retatrutide works · retatrutide regulatory status · GLP-1 vs GIP.
RESEARCH USE ONLY — FULL DISCLAIMER. The products discussed on this page are supplied strictly for laboratory and scientific research purposes. They are not for human or veterinary use, and not for consumption. These statements have not been evaluated by the Food and Drug Administration. Nothing on this page is intended to diagnose, treat, cure, or prevent any disease in humans or animals. Nothing here constitutes medical or veterinary advice or a dosing, preparation, or administration recommendation for any person or animal.
Regulatory status and trial registry data verified 19 August 2026.
